CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
Vous n'êtes pas connecté
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal cancer patients with high...
A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal cancer patients with high...
TUESDAY, Sept. 17, 2024 -- The delivery of early, virtual palliative care has similar effects on quality of life as in-person care in patients with...
TUESDAY, Sept. 10, 2024 -- Omission of 5-fluorouracil (5-FU) from the first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens is not associated with...
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial...